Health Condition 1: N04- Nephrotic syndrome
Conditions
Interventions
Intervention1: Zinc plus standard therapy: Zinc will be given 10 mg per oral OD for 3 months in addition to standard therapy.
Control Intervention1: Standard therapy alone: Prednisolone as per protoco
Sponsors
All India Institute of Medical Sciences, Gorakhpur.
Eligibility
Inclusion criteria
Inclusion criteria: First episode or relapse of nephrotic syndrome
Exclusion criteria
Exclusion criteria: 1. Congenital Nephrotic Syndrome. 2. Steroid Dependent Nephrotic Syndrome or Frequently Relapsing Nephrotic Syndrome currently on low-dose steroids. 3. Steroid Resistant Nephrotic Syndrome. 4. Secondary Nephrotic Syndrome (e.g., diabetes mellitus, systemic lupus erythematosus, infections including hepatitis B/ hepatitis C/ HIV/ tuberculosis, malignancy, drug-induced). 5. Recent (within past 6 months) or concurrent use of other immunosuppressants (levamisole, cyclophosphamide, calcineurin inhibitors, rituximab). 6. Chronic systemic illness (e.g., chronic kidney disease). 7. Hypersensitivity to zinc supplementation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained remission (i.e., no relapse after initial remission)Timepoint: at the end of 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of relapses over the study period.Timepoint: noted on follow-ups during the study period of 6 months.;Time to first relapse after starting supplementation.Timepoint: noted on follow-ups during the study period of 6 months.;Number of infection episodes during follow-up.Timepoint: noted on follow-ups during the study period of 6 months.;Adverse effects of zinc like metallic taste, GI upset and others.Timepoint: noted on follow-ups during the study period of 6 months. | — |
Countries
India
Contacts
Public ContactVaristha Shaw
All India Institute of Medical Sciences, Gorakhpur
Outcome results
None listed